[GRAPHIC OMITTED]


For Immediate Release                                   For further information:
- ---------------------
                                                        Tom  Sommers
                                                        (713)  222-1600

                PHARMAFRONTIERS APPOINTS DAVID B. MCWILLIAMS CEO
           Brian E. Rodriguez Named Director, Head of Audit Committee

HOUSTON, September 21, 2004 - Adult stem cell therapy developer PharmaFrontiers
Corp. (OTCBB:PFTR.OB) has appointed David B. McWilliams as the company's chief
executive officer.

     "Dave's track record as a successful builder of biotechnology companies
provides us with the leadership and experience required to pursue our business
goals of developing and commercializing our technology to use stem cells from
patients' own blood in new therapies with important potential clinical
implications," said PharmaFrontiers Chairman Robert Gow.

     The company also appointed Brian E. Rodriguez to its Board of Directors.
Rodriguez, a Certified Public Accountant and director of finance for JP Mobile
of Dallas, will chair the board's Audit Committee. He previously was a financial
executive with DSC Communications and was part of the business assurance audit
practice of PricewaterhouseCoopers.

     McWilliams, who was also named to the company's board, was previously
president and CEO of Bacterial Barcodes, Inc., a molecular diagnostics company
acquired by a strategic partner earlier this year. His over 30 years of
experience with biopharmaceutical and healthcare companies includes serving as
CEO of Signase, Inc., an M.D. Anderson technology-transfer cancer therapy
company; CEO of Encysive Pharmaceuticals (ENCY), a cardiovascular therapeutics
company for which he raised $250 million in public and strategic financings and
built a portfolio of successful products; and CEO of Zonagen Inc., a
Woodlands-based Baylor University technology transfer company.

     Earlier, McWilliams was a senior executive with Abbott laboratories and a
management consultant with McKinsey & Co. He is a director of Novelos
Therapeutics, Inc., Fairway Medical Systems, the Texas Healthcare and Bioscience
Institute, and the Houston Technology Center. He received an MBA in finance from
the University of Chicago, and a B.A. in chemistry, Phi Beta Kappa, from
Washington and Jefferson College.

     PharmaFrontiers' business strategy is to develop technology using stem
cells derived from patients' own circulating blood to treat major diseases,
including cardiac and pancreatic conditions. The company holds the exclusive
worldwide license from the US Department of Energy's Argonne National Laboratory
for adult pluripotent stem cells derived from peripheral blood.

                                      # # #